Amoxiclav Indications
Amoxiclav (amoxicillin-clavulanate) is indicated for treating bacterial infections caused by beta-lactamase-producing organisms, including acute bacterial rhinosinusitis, acute otitis media, lower respiratory tract infections, skin and soft tissue infections, and urinary tract infections. 1
FDA-Approved Indications
The FDA label specifies the following proven indications for amoxicillin-clavulanate 1:
- Lower Respiratory Tract Infections - caused by beta-lactamase-producing Haemophilus influenzae and Moraxella catarrhalis
- Acute Bacterial Otitis Media - caused by beta-lactamase-producing H. influenzae and M. catarrhalis
- Sinusitis - caused by beta-lactamase-producing H. influenzae and M. catarrhalis
- Skin and Skin Structure Infections - caused by beta-lactamase-producing Staphylococcus aureus, Escherichia coli, and Klebsiella species
- Urinary Tract Infections - caused by beta-lactamase-producing E. coli, Klebsiella species, and Enterobacter species
Critical Limitation
When susceptibility testing shows no beta-lactamase production, amoxicillin alone should be used instead of amoxiclav 1. This is essential for antimicrobial stewardship and reducing unnecessary exposure to clavulanate, which increases gastrointestinal side effects.
Guideline-Supported Clinical Uses
Acute Otitis Media (Pediatric)
High-dose amoxicillin-clavulanate (90 mg/kg/day amoxicillin with 6.4 mg/kg/day clavulanate in 2 divided doses) is first-line therapy for children who: 2
- Have received amoxicillin in the previous 30 days
- Present with concurrent purulent conjunctivitis (otitis-conjunctivitis syndrome)
- Require coverage for beta-lactamase-producing organisms
For uncomplicated cases without recent antibiotic exposure, amoxicillin alone (80-90 mg/kg/day) remains preferred 2. The addition of clavulanate specifically targets H. influenzae and M. catarrhalis resistance patterns.
Acute Bacterial Rhinosinusitis
Adults
For mild disease without recent antibiotic use: Amoxicillin alone is preferred 3.
Amoxicillin-clavulanate (4 g/250 mg daily) is indicated when: 3
- Antibiotic use within the past 4-6 weeks
- Moderate to severe symptoms
- High risk for resistant organisms (age >65, diabetes, immunocompromised, smoker, daycare exposure)
- Geographic areas with >10% penicillin-nonsusceptible S. pneumoniae
Children
High-dose amoxicillin-clavulanate (90 mg/6.4 mg/kg/day) achieves 92% clinical efficacy and 99% bacteriologic efficacy for children with recent antibiotic exposure or moderate disease 4. This represents the highest efficacy among oral options for pediatric sinusitis.
Community-Acquired Pneumonia
Amoxicillin-clavulanate is recommended for: 5
- Adults with risk factors for resistant pathogens
- Patients requiring broader coverage than amoxicillin alone
- Areas with high prevalence of penicillin-resistant S. pneumoniae
The combination provides coverage for both typical respiratory pathogens and beta-lactamase producers, achieving clinical cure rates of 88-92% across respiratory infections 6.
Treatment Failure Scenarios
When first-line amoxicillin fails after 48-72 hours, switch to high-dose amoxicillin-clavulanate (80-90 mg/kg/day amoxicillin) 7. This provides enhanced coverage for resistant organisms while maintaining activity against S. pneumoniae.
Dosing Considerations
High-Dose Regimens
High-dose formulations are specifically designed to overcome resistance: 4
- Adults: 4 g amoxicillin/250 mg clavulanate daily (using extended-release formulation)
- Children: 90 mg/kg/day amoxicillin with 6.4 mg/kg/day clavulanate (14:1 ratio formulation)
The 14:1 ratio reduces diarrhea compared to older 4:1 or 7:1 formulations while maintaining beta-lactamase inhibition 2.
Duration of Therapy
Standard treatment duration is 5-7 days for most indications 3. Shorter courses (5 days) show equivalent efficacy to 10-day regimens with fewer adverse effects, particularly for sinusitis and otitis media.
Common Pitfalls to Avoid
Do not use amoxiclav when amoxicillin alone is sufficient - This unnecessarily increases gastrointestinal side effects (21.6% vs lower rates with amoxicillin) 8 and promotes resistance
Do not prescribe for viral infections - Upper respiratory tract infections are predominantly viral; amoxiclav should only be used when bacterial infection is confirmed or highly suspected 9
Avoid in penicillin-allergic patients - For Type I hypersensitivity, use doxycycline or respiratory fluoroquinolones instead 3. Cephalosporins may be considered for non-Type I reactions
Monitor for hepatotoxicity - Hepatic dysfunction occurs more commonly in elderly males and with prolonged treatment 1. Discontinue if signs of liver dysfunction develop
Safety Profile
Gastrointestinal effects are the most common adverse reactions: 1, 8
- Diarrhea/loose stools: 9-21.6%
- Nausea: 3%
- Vomiting: 1%
These effects are dose-related and primarily attributable to clavulanate. Taking with food reduces nausea and vomiting without significantly affecting absorption 1.
Serious but rare adverse events include: 1
- Hepatic dysfunction (cholestatic jaundice, hepatitis)
- Clostridioides difficile infection
- Hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome)
- Interstitial nephritis
WHO AWaRe Classification
Amoxicillin-clavulanate is classified as an "Access" antibiotic 10, 9, meaning it should be widely available and used as first-line therapy for specific indications. This classification supports its role in antimicrobial stewardship when used appropriately for beta-lactamase-producing organisms.